IP granted by Netherlands Patent Office

IP granted by Netherlands Patent Office

GenLumina is pleased to announce that the Netherlands Patent Office has officially granted our patent based on the application filed on 24 April 2023. This milestone reinforces the scientific foundation of GenLumina’s light-activated nanomedicine platform and...
New Step in Targeted Cancer Therapy

New Step in Targeted Cancer Therapy

Leiden, September 3 – We are thrilled to announce that GenLumina has secured funding from Health~Holland to support a collaborative project with LUMC. This grant will enable us to accelerate the development of our light-activated cancer therapy by expanding our...
UNIIQ invests in GenLumina

UNIIQ invests in GenLumina

A Strong Impulse for Future Cancer Treatments Leiden, June 17 – The early-stage investment fund UNIIQ has made a strategic investment in GenLumina, a promising biotech startup developing groundbreaking technology for cancer treatment using silver and light. This...
GenLumina among the 40 Most Promising Startup 2025

GenLumina among the 40 Most Promising Startup 2025

We are thrilled to announce that we have been selected as one of the 40 startups to compete in the prestigious Academic Startup Competition! This incredible opportunity places us among the most promising science-based startups in the Netherlands for the 2024/2025...